Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)

Key Points

To evaluate the effectiveness and safety profile of durvalumab and tremelimumab in advanced hepatocellular carcinoma.
Analysis of real-world data from the Lombardy Real-World HCC Group
Assessment of treatment-related adverse events
Monitoring dynamic liver function changes
STRIDE shows reproducible effectiveness in clinical practice
Early incidence of adverse events is manageable
Hepatic function declines modestly but remains clinically meaningful

Real-world data shows durvalumab-tremelimumab is effective in advanced hepatocellular carcinoma, suggesting a promising treatment option.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Casadei-Gardini et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share